Cargando…

Identification of hub pathways and drug candidates in gastric cancer through systems biology

Gastric cancer is the fourth cause of cancer death globally, and gastric adenocarcinoma is its most common type. Efforts for the treatment of gastric cancer have increased its median survival rate by only seven months. Due to the relatively low response of gastric cancer to surgery and adjuvant ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Salarikia, Seyed Reza, Kashkooli, Mohammad, Taghipour, Mohammad Javad, Malekpour, Mahdi, Negahdaripour, Manica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160265/
https://www.ncbi.nlm.nih.gov/pubmed/35650297
http://dx.doi.org/10.1038/s41598-022-13052-0
_version_ 1784719233759838208
author Salarikia, Seyed Reza
Kashkooli, Mohammad
Taghipour, Mohammad Javad
Malekpour, Mahdi
Negahdaripour, Manica
author_facet Salarikia, Seyed Reza
Kashkooli, Mohammad
Taghipour, Mohammad Javad
Malekpour, Mahdi
Negahdaripour, Manica
author_sort Salarikia, Seyed Reza
collection PubMed
description Gastric cancer is the fourth cause of cancer death globally, and gastric adenocarcinoma is its most common type. Efforts for the treatment of gastric cancer have increased its median survival rate by only seven months. Due to the relatively low response of gastric cancer to surgery and adjuvant therapy, as well as the complex role of risk factors in its incidences, such as protein-pomp inhibitors (PPIs) and viral and bacterial infections, we aimed to study the pathological pathways involved in gastric cancer development and investigate possible medications by systems biology and bioinformatics tools. In this study, the protein–protein interaction network was analyzed based on microarray data, and possible effective compounds were discovered. Non-coding RNA versus coding RNA interaction network and gene-disease network were also reconstructed to better understand the underlying mechanisms. It was found that compounds such as amiloride, imatinib, omeprazole, troglitazone, pantoprazole, and fostamatinib might be effective in gastric cancer treatment. In a gene-disease network, it was indicated that diseases such as liver carcinoma, breast carcinoma, liver fibrosis, prostate cancer, ovarian carcinoma, and lung cancer were correlated with gastric adenocarcinoma through specific genes, including hgf, mt2a, mmp2, fbn1, col1a1, and col1a2. It was shown that signaling pathways such as cell cycle, cell division, and extracellular matrix organization were overexpressed, while digestion and ion transport pathways were underexpressed. Based on a multilevel systems biology analysis, hub genes in gastric adenocarcinoma showed participation in the pathways such as focal adhesion, platelet activation, gastric acid secretion, HPV infection, and cell cycle. PPIs are hypothesized to have a therapeutic effect on patients with gastric cancer. Fostamatinib seems a potential therapeutic drug in gastric cancer due to its inhibitory effect on two survival genes. However, these findings should be confirmed through experimental investigations.
format Online
Article
Text
id pubmed-9160265
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91602652022-06-03 Identification of hub pathways and drug candidates in gastric cancer through systems biology Salarikia, Seyed Reza Kashkooli, Mohammad Taghipour, Mohammad Javad Malekpour, Mahdi Negahdaripour, Manica Sci Rep Article Gastric cancer is the fourth cause of cancer death globally, and gastric adenocarcinoma is its most common type. Efforts for the treatment of gastric cancer have increased its median survival rate by only seven months. Due to the relatively low response of gastric cancer to surgery and adjuvant therapy, as well as the complex role of risk factors in its incidences, such as protein-pomp inhibitors (PPIs) and viral and bacterial infections, we aimed to study the pathological pathways involved in gastric cancer development and investigate possible medications by systems biology and bioinformatics tools. In this study, the protein–protein interaction network was analyzed based on microarray data, and possible effective compounds were discovered. Non-coding RNA versus coding RNA interaction network and gene-disease network were also reconstructed to better understand the underlying mechanisms. It was found that compounds such as amiloride, imatinib, omeprazole, troglitazone, pantoprazole, and fostamatinib might be effective in gastric cancer treatment. In a gene-disease network, it was indicated that diseases such as liver carcinoma, breast carcinoma, liver fibrosis, prostate cancer, ovarian carcinoma, and lung cancer were correlated with gastric adenocarcinoma through specific genes, including hgf, mt2a, mmp2, fbn1, col1a1, and col1a2. It was shown that signaling pathways such as cell cycle, cell division, and extracellular matrix organization were overexpressed, while digestion and ion transport pathways were underexpressed. Based on a multilevel systems biology analysis, hub genes in gastric adenocarcinoma showed participation in the pathways such as focal adhesion, platelet activation, gastric acid secretion, HPV infection, and cell cycle. PPIs are hypothesized to have a therapeutic effect on patients with gastric cancer. Fostamatinib seems a potential therapeutic drug in gastric cancer due to its inhibitory effect on two survival genes. However, these findings should be confirmed through experimental investigations. Nature Publishing Group UK 2022-06-01 /pmc/articles/PMC9160265/ /pubmed/35650297 http://dx.doi.org/10.1038/s41598-022-13052-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Salarikia, Seyed Reza
Kashkooli, Mohammad
Taghipour, Mohammad Javad
Malekpour, Mahdi
Negahdaripour, Manica
Identification of hub pathways and drug candidates in gastric cancer through systems biology
title Identification of hub pathways and drug candidates in gastric cancer through systems biology
title_full Identification of hub pathways and drug candidates in gastric cancer through systems biology
title_fullStr Identification of hub pathways and drug candidates in gastric cancer through systems biology
title_full_unstemmed Identification of hub pathways and drug candidates in gastric cancer through systems biology
title_short Identification of hub pathways and drug candidates in gastric cancer through systems biology
title_sort identification of hub pathways and drug candidates in gastric cancer through systems biology
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160265/
https://www.ncbi.nlm.nih.gov/pubmed/35650297
http://dx.doi.org/10.1038/s41598-022-13052-0
work_keys_str_mv AT salarikiaseyedreza identificationofhubpathwaysanddrugcandidatesingastriccancerthroughsystemsbiology
AT kashkoolimohammad identificationofhubpathwaysanddrugcandidatesingastriccancerthroughsystemsbiology
AT taghipourmohammadjavad identificationofhubpathwaysanddrugcandidatesingastriccancerthroughsystemsbiology
AT malekpourmahdi identificationofhubpathwaysanddrugcandidatesingastriccancerthroughsystemsbiology
AT negahdaripourmanica identificationofhubpathwaysanddrugcandidatesingastriccancerthroughsystemsbiology